Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders
HONG KONG, Oct 30, 2025 - (ACN Newswire) – Everest Medicines (HKEX:1952.HK) today announced that it has acquired an exclusive license with Visara, Inc. (“Visara”), a subsidiary of NovaBridge Biosciences (formally known as I-Mab, and is a company listed on the Nasdaq Global Market trading under the symbol “NBP”), to…
bubmagOctober 30, 2025